|
Page 7 of 12
MONITORING:
Patients should be monitored with regular laboratory evaluations, including fasting blood (or plasma) glucose determinations, to assess therapeutic response and obtain the minimum effective dosage of antidiabetic medications. Whenever possible, self-monitoring of blood glucose by the patients should be encouraged. Urine glucose concentrations correlate poorly with blood glucose, and should be avoided. Following initiation of treatment and subsequent dosage titration, control can be determined by evaluating glycosylated hemoglobin (HbA1c) levels at intervals of approximately 3 months.
|
